**Supplementary table 1**. Search strategy for Pub Med.

|  |  |  |
| --- | --- | --- |
|  | **Search term** | **PubMed results** |
|  | Systematic review about the use of histology as an endpoint in UC trials |  |
| 1 | Ulcerative colitis | 46 341 |
| 2 | Histological healing OR histological remission OR histological improvement | 20 532 |
| 3 | Infliximab OR adalimumab OR Golimumab OR Certolizumab OR Vedolizumab OR Ustekinumab OR tofacitinib OR Etrolizumab OR Etrasimod OR Ozanimod OR Upadacitinib | 20 676 |
|  | 1+2+3 | 32 |
|  | Systematic review about the impact of histological remission on disease outcomes |  |
| 4 | Outcomes OR hospitalization OR relapse | 1 593 687 |
|  | 1+2+4 | 117 |
| 5 | neoplasia OR dysplasia OR cancer | 3 961 845 |
|  | 1+2+5 | 41 |